Dr. Ruano's Pioneering Contributions to Personalized Medicine Cited for Honor
HARTFORD, Conn. and WASHINGTON, Feb. 12 /PRNewswire/ -- Gualberto Ruano, M.D., Ph.D., was inducted into the American Institute for Medical and Biological Engineering's (AIMBE) College of Fellows today at a ceremony in Washington, DC at the National Academy of Sciences. Recipients of this honor are chosen for exceptional leadership and achievements in medical and biological engineering. Dr. Ruano is President and Chief Executive Officer of Genomas Inc., Director of Genetics Research at Hartford Hospital, and Adjunct Professor in the medical faculties at George Washington University and at the University of Puerto Rico.
At AIMBE (www.aimbe.org), the College of Fellows leads the way in technological advancement, advocating for public policies facilitating progress in medical and biological research and development to benefit the public. As the array of companies and entire industries based on biotechnology and bioengineering has expanded rapidly, AIMBE Fellows have assumed leading roles in both their R&D and management functions, driving the movement of new medical technologies to patient care. Fellows hold numerous patents that have helped make medical and biological engineering a major economic force in the U.S., generating $200 billion in revenue annually and supporting thousands of high-paying jobs.
"I am very honored by this appointment to the AIMBE College of Fellows. Based on my experience at Genomas and Hartford Hospital, advancing DNA-Guided Medicine to clinical practice requires integration of molecular technologies, medical decision algorithms, and physician user interfaces. Such synthesis indeed is a feat of biomedical engineering," said Dr. Ruano. "I look forward to working with AIMBE and its fellows in this quest to bring personalized medicine to healthcare."
In his 25-year scientific and medical career, Dr. Ruano has developed systems for DNA-guided medicine based on genomics, nanoscience, and clinical informatics. At Genomas, he has pioneered physiotypes based on multi-gene markers and bioclinical algorithms for the prediction of human drug response and DNA-guided medicine in patient care.
Genomas is a biomedical company advancing DNA-guided medicine and personalized healthcare. The company develops revolutionary PhyzioType(TM) Systems for DNA-guided diagnosis and prevention of metabolic disorders induced by drugs used to treat diabetes, and cardiovascular and psychiatric illnesses. PhyzioType Systems are designed to provide physicians with an unprecedented capability to select for each patient the safest drug treatment to enhance compliance. Genomas is located in Hartford, CT on the campus of Hartford Hospital. Please visit www.genomas.net for more information.